Latest / WTR Small-Cap Spotlight
NurExone Biologic's Revolutionary Approach to Nerve Regeneration
Send us Fan Mail
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer, along with the company’s Founder, VP Business Development & Active Chairman, Yoram Drucker to talk about NurExone's novel regenerative exosome-based therapies development pipeline for central nervous system injuries, led by spinal cord and optic nerve injuries, both multi-billion-dollar markets. Our conversation covers key differentiators from other developments…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.